Cassava Sciences Beats Q1 Earnings Expectations

The biotech firm reported a narrower-than-expected loss per share for the quarter.

Mar. 12, 2026 at 9:52pm

Got story updates? Submit your updates here. ›

Cassava Sciences (NASDAQ:SAVA), a clinical-stage biopharmaceutical company focused on Alzheimer's disease treatments, reported its first quarter financial results on Thursday. The company posted a loss of $0.26 per share, beating analysts' consensus estimate of a $0.30 per share loss.

Why it matters

Cassava Sciences' performance is closely watched as its lead drug candidate, simufilam, aims to address underlying mechanisms of neurodegeneration in Alzheimer's disease. The company's ability to meet or exceed earnings expectations is seen as a positive sign for the development of its pipeline.

The details

Cassava Sciences reported a net loss of $12.5 million, or $0.26 per share, for the first quarter of 2026. This was better than the $0.30 per share loss that analysts had projected. The company ended the quarter with $114.97 million in market capitalization and $181,000 in cash on hand.

  • Cassava Sciences reported its Q1 2026 earnings results on Thursday, March 12, 2026.
  • The company's shares closed at $2.38 on the day of the earnings release.

The players

Cassava Sciences

A clinical-stage biopharmaceutical company focused on the development of novel therapies and diagnostics for Alzheimer's disease and related neurodegenerative disorders, headquartered in Austin, Texas.

simufilam

Cassava Sciences' lead drug candidate, a proprietary small molecule that aims to restore normal shape and function to the scaffolding protein filamin A, which has been implicated in impaired neuronal signaling and inflammation in Alzheimer's patients.

Got photos? Submit your photos here. ›

The takeaway

Cassava Sciences' ability to beat earnings expectations for the first quarter is a positive sign for the development of its Alzheimer's disease pipeline, particularly its lead drug candidate simufilam. However, the company still faces significant challenges in advancing its therapies through clinical trials and regulatory approval.